Chronic idiopathic constipation (CIC) is a health condition in which a person experiences chronic symptoms of constipation, yet no visible cause can be identified through standard diagnostic testing. The term idiopathic is used because it means there is no known cause. CIC includes symptoms of difficult, infrequent, or incomplete bowel movements.
In 2017, the global Chronic Idiopathic Constipation (CIC) Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Chronic Idiopathic Constipation (CIC) Drugs market based on company, product type, application and key regions.
This report studies the global market size of Chronic Idiopathic Constipation (CIC) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Chronic Idiopathic Constipation (CIC) Drugs in these regions.
This research report categorizes the global Chronic Idiopathic Constipation (CIC) Drugs market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.
The various contributors involved in the value chain of Chronic Idiopathic Constipation (CIC) Drugs include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Chronic Idiopathic Constipation (CIC) Drugs include
Actavis
Chugai Pharmaceutical
Ferring International Center
Synergy Pharmaceuticals
Pfizer
GlaxoSmithKline
Roche Holding
Sanofi
Bayer
Salix Pharmaceuticals
Sucampo Pharmaceuticals
Ironwood Pharmaceuticals
Progenics Pharmaceuticals
Market Size Split by Type
Lubiprostone
Linaclotide
Others
Market Size Split by Application
Hospitals & Clinics
Ambulatory Surgical Centres
Long Term Care Centres
Others
Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Chronic Idiopathic Constipation (CIC) Drugs market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Chronic Idiopathic Constipation (CIC) Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Chronic Idiopathic Constipation (CIC) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Chronic Idiopathic Constipation (CIC) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Chronic Idiopathic Constipation (CIC) Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Chronic Idiopathic Constipation (CIC) Drugs are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chronic Idiopathic Constipation (CIC) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
In 2017, the global Chronic Idiopathic Constipation (CIC) Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Chronic Idiopathic Constipation (CIC) Drugs market based on company, product type, application and key regions.
This report studies the global market size of Chronic Idiopathic Constipation (CIC) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Chronic Idiopathic Constipation (CIC) Drugs in these regions.
This research report categorizes the global Chronic Idiopathic Constipation (CIC) Drugs market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.
The various contributors involved in the value chain of Chronic Idiopathic Constipation (CIC) Drugs include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Chronic Idiopathic Constipation (CIC) Drugs include
Actavis
Chugai Pharmaceutical
Ferring International Center
Synergy Pharmaceuticals
Pfizer
GlaxoSmithKline
Roche Holding
Sanofi
Bayer
Salix Pharmaceuticals
Sucampo Pharmaceuticals
Ironwood Pharmaceuticals
Progenics Pharmaceuticals
Market Size Split by Type
Lubiprostone
Linaclotide
Others
Market Size Split by Application
Hospitals & Clinics
Ambulatory Surgical Centres
Long Term Care Centres
Others
Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Chronic Idiopathic Constipation (CIC) Drugs market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Chronic Idiopathic Constipation (CIC) Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Chronic Idiopathic Constipation (CIC) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Chronic Idiopathic Constipation (CIC) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Chronic Idiopathic Constipation (CIC) Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Chronic Idiopathic Constipation (CIC) Drugs are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chronic Idiopathic Constipation (CIC) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
1.1 Chronic Idiopathic Constipation (CIC) Drugs Product
1.2 Key Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by Type
1.4.2 Lubiprostone
1.4.3 Linaclotide
1.4.4 Others
1.5 Market by Application
1.5.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by Application
1.5.2 Hospitals & Clinics
1.5.3 Ambulatory Surgical Centres
1.5.4 Long Term Care Centres
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size
2.1.1 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue 2016-2025
2.1.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales 2016-2025
2.2 Chronic Idiopathic Constipation (CIC) Drugs Growth Rate by Regions
2.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Regions
2.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Chronic Idiopathic Constipation (CIC) Drugs Sales by Manufacturers
3.1.1 Chronic Idiopathic Constipation (CIC) Drugs Sales by Manufacturers
3.1.2 Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Manufacturers
3.1.3 Global Chronic Idiopathic Constipation (CIC) Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Chronic Idiopathic Constipation (CIC) Drugs Revenue by Manufacturers
3.2.1 Chronic Idiopathic Constipation (CIC) Drugs Revenue by Manufacturers (2016-2018)
3.2.2 Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Manufacturers (2016-2018)
3.3 Chronic Idiopathic Constipation (CIC) Drugs Price by Manufacturers
3.4 Chronic Idiopathic Constipation (CIC) Drugs Manufacturing Base Distribution, Product Types
3.4.1 Chronic Idiopathic Constipation (CIC) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Chronic Idiopathic Constipation (CIC) Drugs Product Category
3.4.3 Date of International Manufacturers Enter into Chronic Idiopathic Constipation (CIC) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type
4.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Type
4.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type
4.3 Chronic Idiopathic Constipation (CIC) Drugs Price by Type
5 Breakdown Data by Application
5.1 Overview
5.2 Global Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Application
6 North America
6.1 North America Chronic Idiopathic Constipation (CIC) Drugs by Countries
6.1.1 North America Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
6.1.2 North America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Chronic Idiopathic Constipation (CIC) Drugs by Type
6.3 North America Chronic Idiopathic Constipation (CIC) Drugs by Application
6.4 North America Chronic Idiopathic Constipation (CIC) Drugs by Company
7 Europe
7.1 Europe Chronic Idiopathic Constipation (CIC) Drugs by Countries
7.1.1 Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
7.1.2 Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Chronic Idiopathic Constipation (CIC) Drugs by Type
7.3 Europe Chronic Idiopathic Constipation (CIC) Drugs by Application
7.4 Europe Chronic Idiopathic Constipation (CIC) Drugs by Company
8 Asia Pacific
8.1 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by Countries
8.1.1 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
8.1.2 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by Type
8.3 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by Application
8.4 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by Company
9 Central & South America
9.1 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by Countries
9.1.1 Central & South America Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
9.1.2 Central & South America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by Type
9.3 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by Application
9.4 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by Company
10 Middle East and Africa
10.1 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by Countries
10.1.1 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
10.1.2 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by Type
10.3 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by Application
10.4 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by Company
11 Company Profiles
11.1 Actavis
11.1.1 Actavis Company Details
11.1.2 Company Description
11.1.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.1.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.1.5 Recent Development
11.2 Chugai Pharmaceutical
11.2.1 Chugai Pharmaceutical Company Details
11.2.2 Company Description
11.2.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.2.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.2.5 Recent Development
11.3 Ferring International Center
11.3.1 Ferring International Center Company Details
11.3.2 Company Description
11.3.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.3.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.3.5 Recent Development
11.4 Synergy Pharmaceuticals
11.4.1 Synergy Pharmaceuticals Company Details
11.4.2 Company Description
11.4.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.4.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.4.5 Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Company Description
11.5.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.5.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.5.5 Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 Company Description
11.6.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.6.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.6.5 Recent Development
11.7 Roche Holding
11.7.1 Roche Holding Company Details
11.7.2 Company Description
11.7.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.7.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.7.5 Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Company Description
11.8.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.8.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.8.5 Recent Development
11.9 Bayer
11.9.1 Bayer Company Details
11.9.2 Company Description
11.9.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.9.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.9.5 Recent Development
11.10 Salix Pharmaceuticals
11.10.1 Salix Pharmaceuticals Company Details
11.10.2 Company Description
11.10.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.10.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.10.5 Recent Development
11.11 Sucampo Pharmaceuticals
11.12 Ironwood Pharmaceuticals
11.13 Progenics Pharmaceuticals
12 Market Opportunities, Challenges, Risks and Influences Factors Analysis
12.1 Market Opportunities and Drivers
12.2 Market Challenges
12.3 Market Risks/Restraints
12.4 Key World Economic Indicators
13 Value Chain and Sales Channels Analysis
13.1 Value Chain Analysis
13.1.1 Typical Suppliers of Key Chronic Idiopathic Constipation (CIC) Drugs Raw Material
13.1.2 Chronic Idiopathic Constipation (CIC) Drugs Customers
13.2 Sales Channels Analysis
13.2.1 Sales Channels Analysis
13.2.2 Distributors
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer
1 Study Coverage
1.1 Chronic Idiopathic Constipation (CIC) Drugs Product
1.2 Key Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by Type
1.4.2 Lubiprostone
1.4.3 Linaclotide
1.4.4 Others
1.5 Market by Application
1.5.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by Application
1.5.2 Hospitals & Clinics
1.5.3 Ambulatory Surgical Centres
1.5.4 Long Term Care Centres
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size
2.1.1 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue 2016-2025
2.1.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales 2016-2025
2.2 Chronic Idiopathic Constipation (CIC) Drugs Growth Rate by Regions
2.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Regions
2.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Chronic Idiopathic Constipation (CIC) Drugs Sales by Manufacturers
3.1.1 Chronic Idiopathic Constipation (CIC) Drugs Sales by Manufacturers
3.1.2 Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Manufacturers
3.1.3 Global Chronic Idiopathic Constipation (CIC) Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Chronic Idiopathic Constipation (CIC) Drugs Revenue by Manufacturers
3.2.1 Chronic Idiopathic Constipation (CIC) Drugs Revenue by Manufacturers (2016-2018)
3.2.2 Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Manufacturers (2016-2018)
3.3 Chronic Idiopathic Constipation (CIC) Drugs Price by Manufacturers
3.4 Chronic Idiopathic Constipation (CIC) Drugs Manufacturing Base Distribution, Product Types
3.4.1 Chronic Idiopathic Constipation (CIC) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Chronic Idiopathic Constipation (CIC) Drugs Product Category
3.4.3 Date of International Manufacturers Enter into Chronic Idiopathic Constipation (CIC) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type
4.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Type
4.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type
4.3 Chronic Idiopathic Constipation (CIC) Drugs Price by Type
5 Breakdown Data by Application
5.1 Overview
5.2 Global Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Application
6 North America
6.1 North America Chronic Idiopathic Constipation (CIC) Drugs by Countries
6.1.1 North America Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
6.1.2 North America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Chronic Idiopathic Constipation (CIC) Drugs by Type
6.3 North America Chronic Idiopathic Constipation (CIC) Drugs by Application
6.4 North America Chronic Idiopathic Constipation (CIC) Drugs by Company
7 Europe
7.1 Europe Chronic Idiopathic Constipation (CIC) Drugs by Countries
7.1.1 Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
7.1.2 Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Chronic Idiopathic Constipation (CIC) Drugs by Type
7.3 Europe Chronic Idiopathic Constipation (CIC) Drugs by Application
7.4 Europe Chronic Idiopathic Constipation (CIC) Drugs by Company
8 Asia Pacific
8.1 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by Countries
8.1.1 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
8.1.2 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by Type
8.3 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by Application
8.4 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by Company
9 Central & South America
9.1 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by Countries
9.1.1 Central & South America Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
9.1.2 Central & South America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by Type
9.3 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by Application
9.4 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by Company
10 Middle East and Africa
10.1 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by Countries
10.1.1 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
10.1.2 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by Type
10.3 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by Application
10.4 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by Company
11 Company Profiles
11.1 Actavis
11.1.1 Actavis Company Details
11.1.2 Company Description
11.1.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.1.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.1.5 Recent Development
11.2 Chugai Pharmaceutical
11.2.1 Chugai Pharmaceutical Company Details
11.2.2 Company Description
11.2.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.2.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.2.5 Recent Development
11.3 Ferring International Center
11.3.1 Ferring International Center Company Details
11.3.2 Company Description
11.3.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.3.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.3.5 Recent Development
11.4 Synergy Pharmaceuticals
11.4.1 Synergy Pharmaceuticals Company Details
11.4.2 Company Description
11.4.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.4.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.4.5 Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Company Description
11.5.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.5.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.5.5 Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 Company Description
11.6.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.6.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.6.5 Recent Development
11.7 Roche Holding
11.7.1 Roche Holding Company Details
11.7.2 Company Description
11.7.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.7.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.7.5 Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Company Description
11.8.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.8.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.8.5 Recent Development
11.9 Bayer
11.9.1 Bayer Company Details
11.9.2 Company Description
11.9.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.9.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.9.5 Recent Development
11.10 Salix Pharmaceuticals
11.10.1 Salix Pharmaceuticals Company Details
11.10.2 Company Description
11.10.3 Sales, Revenue and Gross Margin of Chronic Idiopathic Constipation (CIC) Drugs
11.10.4 Chronic Idiopathic Constipation (CIC) Drugs Product Description
11.10.5 Recent Development
11.11 Sucampo Pharmaceuticals
11.12 Ironwood Pharmaceuticals
11.13 Progenics Pharmaceuticals
12 Market Opportunities, Challenges, Risks and Influences Factors Analysis
12.1 Market Opportunities and Drivers
12.2 Market Challenges
12.3 Market Risks/Restraints
12.4 Key World Economic Indicators
13 Value Chain and Sales Channels Analysis
13.1 Value Chain Analysis
13.1.1 Typical Suppliers of Key Chronic Idiopathic Constipation (CIC) Drugs Raw Material
13.1.2 Chronic Idiopathic Constipation (CIC) Drugs Customers
13.2 Sales Channels Analysis
13.2.1 Sales Channels Analysis
13.2.2 Distributors
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer
Research Methodology
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analysing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.